Skip to main content

Table 2 Summary of adverse drug reactions occurring in the safety population

From: Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

 

155 U onabotulinumtoxinA

156–195 U onabotulinumtoxinA

(n = 218)

(n = 77)

Adverse drug reaction

51 (23.4)

10 (13.0)

None

167 (76.6)

67 (87.0)

Mild

24 (11.0)

5 (6.5)

Moderate

18 (8.3)

3 (3.9)

Severe

9 (4.1)

2 (2.6)

Serious adverse drug reaction

3 (1.4)

1 (1.3)

  1. aParticipants treated with onabotulinumtoxinA in at least 4 Visits.
  2. Data are n (%). U, units.